Nicotinamide adenine dinucleotide — NAD+ — is one of the most consequential molecules in cellular biology, and yet almost nobody outside biochemistry knew its name until the last decade of longevity research made it a household supplement-aisle term. NAD+ is not a nutrient itself; it is a coenzyme, meaning it doesn't get used up in a single reaction but instead shuttles electrons between hundreds of metabolic reactions, cycling continuously between its oxidized form (NAD+) and reduced form (NADH). Every cell in the body depends on NAD+ to run the electron transport chain and generate ATP. Without functioning NAD+ metabolism, mitochondrial energy production collapses.
But NAD+'s importance to the aging field goes beyond energy metabolism. NAD+ is also the obligate substrate — not just a helper molecule, but a molecule that gets consumed and must be replenished — for two families of enzymes central to longevity biology: the sirtuins (SIRT1–7, deacetylases that regulate gene expression, mitochondrial biogenesis, and stress resistance) and PARPs (poly-ADP-ribose polymerases, the primary DNA damage repair enzymes). A third NAD+-consuming enzyme, CD38, degrades NAD+ as part of immune signaling and rises sharply with age and chronic inflammation. All three compete for the same finite NAD+ pool — and as CD38 activity rises and PARP activation increases with accumulated DNA damage, sirtuins are increasingly starved of the substrate they need to function. This is the mechanistic core of the "NAD+ decline" story: it's not that cells stop wanting to repair DNA or regulate genes — it's that the fuel supply for those processes runs short precisely when demand for DNA repair is highest.
Sirtuins were the molecules that first put NAD+ on the map in aging science. SIRT1, the most studied of the seven mammalian sirtuins, deacetylates a wide range of targets including PGC-1α (the master regulator of mitochondrial biogenesis), FOXO transcription factors (stress resistance and autophagy genes), and p53. Because sirtuins require NAD+ as a cofactor for every catalytic cycle, their activity is directly gated by NAD+ availability — when NAD+ falls, sirtuin activity falls with it, regardless of how much sirtuin protein is present. This is fundamentally different from most enzyme regulation, which works through changing protein expression; sirtuins are metabolically throttled by substrate scarcity.
PARP1, meanwhile, is activated by DNA strand breaks and consumes large quantities of NAD+ to synthesize poly-ADP-ribose chains that recruit repair machinery to damage sites. Since DNA damage accumulates with age — from replication errors, oxidative stress, and environmental exposure — PARP activation increases with age, and each activation event depletes local NAD+ pools further. This creates a vicious cycle: more damage requires more PARP activity, which consumes more NAD+, which leaves less NAD+ for sirtuins to perform the very maintenance functions (mitochondrial quality control, stress response) that would have prevented some of that damage in the first place.
CD38 compounds the problem further. Originally studied as an immune cell surface marker, CD38 is now understood to be the primary NAD+-degrading enzyme in mammalian tissue — with a Michaelis constant (affinity for NAD+) high enough that even modest CD38 expression can dominate the competition for the NAD+ pool over sirtuins. CD38 expression rises with age and with senescent cell burden (senescent cells recruit CD38-expressing immune cells as part of the SASP-driven inflammatory response), meaning that as the body accumulates senescent cells, it simultaneously loses more of its available NAD+ to CD38 degradation — a second feedback loop layered on top of the PARP cycle.
Neither NMN (nicotinamide mononucleotide) nor NR (nicotinamide riboside) is NAD+ itself — both are precursor molecules, one step removed from NAD+ in the salvage biosynthesis pathway, taken as supplements because NAD+ itself cannot efficiently cross cell membranes intact. The salvage pathway runs: nicotinamide → NMN → NAD+ (via the enzyme NMNAT), and NR is converted to NMN first (via the enzyme NRK1/2) before following the same final step.
For years, exactly how NMN entered cells was unclear, given that NMN is a larger, charged molecule not obviously suited to crossing lipid membranes. Yoshino's own group resolved this in a 2021 Science paper identifying Slc12a8 as a dedicated NMN transporter, expressed prominently in the small intestine — providing a direct transport mechanism for orally administered NMN rather than requiring extracellular breakdown to nicotinamide riboside first, as some researchers had proposed. This finding gave NMN's oral bioavailability story a firmer mechanistic foundation.
NR, by contrast, has a longer clinical track record in humans, beginning with Charles Brenner's foundational biochemistry work and Trammell's 2016 first-in-human pharmacokinetic study. NR is well absorbed orally, is converted efficiently via NRK1, and has been tested in more completed human trials to date than NMN, including the ChromaDex-sponsored Elysium Health "Basis" formulation trials. In practice, the two precursors are best understood as two different on-ramps to the same NAD+ destination — the meaningful differences are in delivery form (many NMN products are formulated as sublingual powders or lozenges to bypass first-pass gut metabolism, while NR is typically an oral capsule) and depth of human trial data (NR ahead on trial count, NMN ahead on the most detailed single mechanistic dose-response NEJM data).
| Trial / Study | Design | Key Finding | Significance |
|---|---|---|---|
| Mills et al. 2016 (Cell Metabolism) | Aged mice, long-term NMN administration | Restored NAD+ levels, improved mitochondrial function, insulin sensitivity, and physical activity in aged mice; mitigated age-associated weight gain | Established chronic (not just acute) NMN dosing benefit in aging rodents, extending Sinclair's 2013 acute findings |
| Trammell et al. 2016 (Nature Communications) | First human pharmacokinetic trial of oral NR, single and multiple doses | NR safely and dose-dependently elevated blood NAD+ metabolome in healthy adults with no serious adverse effects | First direct human proof that an NAD+ precursor supplement raises human NAD+ levels — foundational safety and PK data |
| Yoshino et al. 2021 (NEJM) | RCT, 25 postmenopausal women with prediabetes, 250mg/day oral NMN, 10 weeks | 38% increase in muscle NAD+ metabolome; improved skeletal muscle insulin sensitivity, insulin signaling, and muscle remodeling gene expression | First placebo-controlled human RCT linking NMN-driven NAD+ elevation to a measurable downstream metabolic benefit, not just biomarker change |
| Elysium Health "Basis" Phase 2 (Nicotinamide riboside + pterostilbene) | RCT, healthy adults, NR combined with pterostilbene (a sirtuin-activating polyphenol) | Significant, sustained increase in blood NAD+ levels (~40%) over 8 weeks; well tolerated | Demonstrated durability of NAD+ elevation over longer supplementation windows with a combination formulation |
David Sinclair's lab (Gomes et al. 2013, Cell) treated 22-month-old mice — roughly equivalent to 60-year-old humans — with NMN for just one week and found that multiple measures of mitochondrial and muscle function shifted toward those of 6-month-old mice. The mechanism proposed: restoring NAD+ reactivated SIRT1-mediated communication between the nucleus and mitochondria (a signaling axis the researchers termed part of the broader "mitochondrial-nuclear communication" decline in aging), improving oxidative phosphorylation capacity and reducing markers of sarcopenia-associated muscle degeneration. This single study, more than any other, catalyzed the modern NMN supplement industry — though it's worth noting the effect was measured over one week in mice, and translating both the dose and duration relationships to decades-long human aging remains an active research question.
Niacin (nicotinic acid) and nicotinamide (niacinamide) are both older, well-established forms of vitamin B3 that also feed into NAD+ biosynthesis — but they come with distinct drawbacks that NMN and NR were specifically developed to avoid. Niacin at NAD+-relevant doses (typically 500mg+) reliably causes a histamine-mediated flushing reaction — intense skin redness, warmth, and itching — that many people find intolerable, even though it is not medically dangerous. Nicotinamide avoids the flushing problem, but Rajman et al. 2018 (Cell Metabolism, a key review of sirtuin-activating compounds) highlights that nicotinamide at high doses is itself a direct inhibitor of sirtuin enzymatic activity, meaning that pushing nicotinamide intake too high can work against the very sirtuin-activation goal that NAD+ precursor supplementation is meant to achieve. This is the core reason the longevity field shifted research focus toward NMN and NR — both bypass the flushing issue and, unlike nicotinamide, do not directly inhibit sirtuins at the concentrations achieved through supplementation.
If CD38 is a primary driver of age-related NAD+ consumption, an intuitive complementary strategy is to inhibit CD38 activity while simultaneously boosting NAD+ precursor supply — rather than only increasing supply against an ever-growing rate of consumption. Two dietary flavonoids have emerged as the most-studied natural CD38 inhibitors: apigenin (found concentrated in chamomile and parsley) and quercetin (found in onions, apples, and capers, and already widely used as a senolytic agent alongside dasatinib). Both have demonstrated CD38-inhibiting activity in preclinical models, with the proposed benefit being a compounding effect — precursor supplementation raises the NAD+ synthesis rate while CD38 inhibition reduces the degradation rate, together producing a larger net increase in steady-state NAD+ than either intervention alone.
It's worth being precise about the evidence tier here: the CD38-inhibition-plus-precursor stacking rationale is mechanistically sound and supported by preclinical (cell and rodent) data, but there is not yet a large, dedicated human RCT directly comparing NMN/NR alone against NMN/NR plus apigenin or quercetin on hard NAD+ or clinical outcomes. This is a biologically plausible and low-risk combination given both compounds' established safety profiles, but it should be understood as an evidence-informed hypothesis rather than a proven human protocol.
Before — or alongside — supplementing with NMN or NR, several free interventions meaningfully affect NAD+ metabolism. Exercise is the best-supported: both endurance and resistance training upregulate NAMPT, the rate-limiting enzyme in the NAD+ salvage pathway, increasing the body's own capacity to regenerate NAD+ from nicotinamide rather than relying entirely on exogenous precursor supply. Fasting produces a rapid effect — NAD+ levels can rise by roughly 50% within 24 hours of caloric restriction as the ratio of NAD+ to NADH shifts and AMPK signaling (activated by energy scarcity) further supports NAD+-related gene expression. Cold exposure (cold showers, cold plunge) activates brown adipose tissue thermogenesis, which is itself NAD+-dependent and appears to further support the broader mitochondrial biogenesis pathways that sirtuins regulate. None of these lifestyle levers require ongoing purchase decisions, and the evidence for exercise's NAMPT-boosting effect in particular is more extensively replicated in humans than most supplement claims in this space.
NMN — 250–500mg/day: The Yoshino 2021 NEJM trial used 250mg/day and demonstrated both NAD+ elevation and functional insulin-sensitivity benefit; many current protocols extend to 500mg/day based on dose-ranging safety data, though the incremental benefit above 250mg has not been as rigorously demonstrated in controlled human trials. Sublingual or lozenge forms are commonly used based on the theory that they partially bypass first-pass gut metabolism, though head-to-head bioavailability data in humans comparing delivery forms remains limited.
NR — 300–1,000mg/day: Trammell's original human PK work and subsequent Elysium Basis trials used doses in the 300–1,000mg/day range, generally taken in the morning; NR's longer track record in completed human RCTs makes dosing guidance somewhat better established than for NMN, with 300mg/day as a reasonable starting point and up to 1,000mg/day used in some trial arms without safety signal.
Timing: Take NAD+ precursors in the morning — NAD+ metabolism has circadian dynamics, and morning dosing avoids any theoretical interference with the nighttime NAD+/sirtuin dynamics involved in circadian clock gene regulation (CLOCK/BMAL1 are themselves sirtuin substrates).
Stack consideration: Pairing an NMN or NR precursor with a CD38 inhibitor (apigenin or quercetin) and a sirtuin activator (resveratrol, though its bioavailability and mechanism remain debated) reflects the current "supply plus reduced consumption plus downstream activation" theory — reasonable given the safety profile of each individual component, but not validated as a combined stack in a dedicated human trial.